Home
About Us
Company Profile Development History Corporate Culture

     Aurovitas Pharma Taizhou Co., Ltd. was established in China Medical City in January 2018, with a registered capital of USD 90.8 million. Aurovitas is primarily engaged in the production and R&D of OSD. The plant covers an area of approximately 97 mu, including production and auxiliary facilities such as quality block and OSD production workshop.


News
Information Feedback
Contact Us
EN / 中

Your current location:

Home

About Us

Company Profile

      Aurovitas Pharma Taizhou Co., Ltd. was established in China Medical City in January 2018, with a registered capital of USD 90.8 million.  Aurovitas is primarily engaged in the production and R&D of OSD. The plant covers an area of approximately 97 mu, including production and auxiliary facilities such as quality block and OSD production workshop.


Development History
  • Passed EU GMP Inspection in June.
2023
  • PQ completion of large-scale commercial batch equipment and facilities
  • Completion of PQ for small commercial batch equipment and facilities
  • Complete 14 product technology transfers
  • More than 50 imported product registrations have been completed
2022
  • QC laboratory enters GMP status
  • Small commercial batch production area completed decoration
  • Obtaining a Chinese drug production license
2021
  • Internal decoration of factory buildings and equipment procurement
  • QC laboratory instruments enter the IOQ stage
2020
  • The first drug registration materials in January are officially submitted
  • Top sealing of the quality inspection comprehensive building in October
  • Top of the production workshop building in November
2019
  • On January 29th, Anruovita Pharmaceutical Taizhou Co., Ltd. was registered and established
  • On July 20th, the self built factory building broke ground and started construction
2018
2023
2022
2021
2020
2019
2018

Corporate Culture

Make good use of talents
Employees are the most valuable asset of a company

Staff

Responsibility

Idea